Effect of ethnicity and chemotherapy (mFOLFOX6) on zolbetuximab pharmacokinetics in patients with claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ).

被引：0
|
作者：
Lee, Keun-Wook
Klempner, Samuel J.
Yang, Jianning
Desai, Amit
Yamada, Akihiro
Ueno, Yoko
Wojtkowski, Tomasz
Park, Jung Wook
Pavese, Janet
Loupakis, Fotios
Bang, Yung-Jue
Shitara, Kohei
机构：
[1] Seoul Natl Univ, Bundang Hosp, Coll, Seongnam, South Korea
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Astellas Pharma Global Dev, Northbrook, IL USA
[4] Astellas Pharma Global Dev Inc, Northbrook, IL USA
[5] Univ Pisana, Univ Azienda Osped, Pisa, Italy
[6] Seoul Natl Univ Hosp, Seoul, South Korea
[7] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e16078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16078
引用
收藏
页数：4
相关论文
共 50 条
  • [41] A phase III trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
    Xu, Rui-hua
    Arkenau, Hendrik-Tobias
    Bang, Yung-Jue
    Denlinger, Crystal S.
    Kato, Ken
    Tabernero, Josep
    Wang, Jin
    Li, Jiang
    Castro, Henry
    Moehler, Markus Hermann
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
    Shah, Manish A.
    Starodub, Alexander
    Sharma, Sunil
    Berlin, Jordan
    Patel, Manish
    Wainberg, Zev A.
    Chaves, Jorge
    Gordon, Michael
    Windsor, Kevin
    Brachmann, Carrie Baker
    Huang, Xi
    Vosganian, Greg
    Maltzman, Julia D.
    Smith, Victoria
    Silverman, Jeffrey A.
    Lenz, Heinz-Josef
    Bendell, Johanna C.
    CLINICAL CANCER RESEARCH, 2018, 24 (16) : 3829 - 3837
  • [43] Phase II study of cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Pinto, C.
    Di Fabio, F.
    Barone, C.
    Siena, S.
    Falcone, A.
    Cascinu, S.
    Rojas, Llimpe F.
    Artale, S.
    Schinzari, G.
    Giaquinta, S.
    Mutri, V
    Martoni, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 9 - 9
  • [44] Phase III study of first-line zolbetuximab plus CAPOX versus placebo plus CAPOX in Claudin 18.2+/HER2-advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW.
    Shah, Manish A.
    Ajani, Jaffer A.
    Al-Batran, Salah-Eddin
    Bang, Yung-Jue
    Catenacci, Daniel
    Enzinger, Peter C.
    Ilson, David H.
    Kim, Sunnie
    Lordick, Florian
    Shitara, Kohei
    Van Cutsem, Eric
    Arozullah, Ahsan
    Park, Jung Wook
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
    Tabernero, Josep
    Van Cutsem, Eric
    Bang, Yung-Jue
    Fuchs, Charles S.
    Wyrwicz, Lucjan
    Lee, Keun Wook
    Kudaba, Iveta
    Garrido, Marcelo
    Chung, Hyun Cheol
    Salguero, Hugo Raul Castro
    Mansoor, Wasat
    Braghiroli, Maria Ignez Freitas Melro
    Goekkurt, Eray
    Chao, Joseph
    Wainberg, Zev A.
    Kher, Uma
    Shah, Sukrut
    Kang, SoonMo Peter
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
  • [46] Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials
    Lordick, F.
    Van Cutsem, E.
    Shitara, K.
    Xu, R. -H.
    Ajani, J. A.
    Shah, M. A.
    Oh, M.
    Ganguli, A.
    Chang, L.
    Rhoten, S.
    Bhattacharya, P.
    Matsangou, M.
    Park, J. W.
    Pophale, R.
    Ranganath, R.
    Kang, Y. -K.
    ESMO OPEN, 2024, 9 (08)
  • [47] Pembrolizumab plus chemotherapy for previously untreated, HER2-negative unresectable or metastatic advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859.
    Tabernero, Josep
    Bang, Yung-Jue
    Van Cutsem, Eric
    Fuchs, Charles S.
    Janjigian, Yelena Y.
    Bhagia, Pooja
    Li Kan
    Adelberg, David E.
    Kui, Qin Shu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [48] Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.
    Li, Hongli
    Deng, Jingyu
    Ge, Shaohua
    Zang, Fenglin
    Zhang, Le
    Ren, Peng
    Wang, Baogui
    Cao, Fuliang
    Deng, Ting
    Liu, Rui
    Ning, Tao
    Yang, Yuchong
    Bai, Ming
    Wang, Xia
    Ji, Zhi
    Duan, Jingjing
    Liu, Yong
    Zhou, Dejun
    Liang, Han
    Ba, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Real-world practices and physician perspectives on biomarker testing and treatment patterns in patients with locally advanced unresectable or metastatic (La/m) gastric/gastroesophageal junction (G/GEJ) adenocarcinoma in the US
    Lewis, K.
    Fuldeore, R.
    Braun, S.
    Gourgioti, G.
    Lambert, A.
    Thomason, G.
    Bernacki, K.
    Yang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S245 - S245
  • [50] Safety, tolerability, and pharmacokinetics (PK) of rilotumumab (R) combined with cisplatin (C) and capecitabine (X) in Japanese patients (pts) with MET-positive metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
    Doi, Toshihiko
    Yamaguchi, Kensei
    Komatsu, Yoshito
    Muro, Kei
    Nishina, Tomohiro
    Nakajima, Takako Eguchi
    Lizambri, Richard
    Loh, Elwyn
    Tang, Rui
    Zhang, Yilong
    Yasui, Hirofumi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345